Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146072

Pw146072 View Pathway
drug action

Rolapitant Drug Metabolism Action Pathway

Homo sapiens

PW101965

Pw101965 View Pathway
disease

Role of Tob in T-cell activation

Homo sapiens
Tob, a member of an anti-proliferative gene family, is highly expressed in anergic T cell clones. Tob is also expressed in unstimulated peripheral blood T lymphocytes and down-regulated during activation. Forced expression of Tob inhibits T cell proliferation and transcription of cytokines and cyclins. In contrast, suppression of Tob with an antisense oligonucleotide augments CD3-mediated responses and abrogates the requirement of costimulation for maximal proliferation and cytokine secretion. Tob associated with Smad2 and Smad4 and enhances Smad DNA-binding. The inhibitory effect of Tob on interleukin 2 (IL-2) transcription is not mediated by blockade of NFAT, AP-1 or NF-kappaB transactivation but by enhancement of Smad binding on the -105 negative regulatory element of the IL-2 promoter. Thus, T cell quiescence is an actively maintained phenotype that must be suppressed for T cell activation to occur.

PW000703

Pw000703 View Pathway
drug action

Rolitetracycline Action Pathway

Homo sapiens
Rolitetracycline is a broad spectrum second antibiotic formed by the N-aminomethylation of the carboxamide function of tetracycline. Classified as a second generation tetracycline due to it’s semi-synthesis, rolitetracycline like tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This prevents tRNA from interacting with the ribosome ultimately halting the addition of amino acids to peptide chains used in protein synthesis.

PW128360

Pw128360 View Pathway
drug action

Rolitetracycline Action Pathway (new)

Homo sapiens
Rolitetracycline, a broad-spectrum tetracycline antibiotic, is used for treatment when higher concentrations are required. Rolitetracycline passively diffuses through porin channels into bacterial cells and binds to the 30S ribosomal subunit. By binding to 30S subunit which prevents tRNA binding to mRNA ribosome complex and disrupting protein synthesis. Milk and dairy products should be avoided in order to optimize the absorption of rolitetracycline.

PW145367

Pw145367 View Pathway
drug action

Rolitetracycline Drug Metabolism Action Pathway

Homo sapiens

PW145669

Pw145669 View Pathway
drug action

Romidepsin Drug Metabolism Action Pathway

Homo sapiens

PW144397

Pw144397 View Pathway
drug action

Ropinirole Drug Metabolism Action Pathway

Homo sapiens

PW128056

Pw128056 View Pathway
drug action

Ropinirole Mechanism of Action Action Pathway

Homo sapiens
Ropinirole is a nonergoline dopamine agonist. used in the management in early and late Parkinson's disease. Ropinirole has a high affinity for and stimulates the post-synaptic dopamine receptors D2 in the central and peripheral nervous systems. The dopamine receptors (D2) are g-protein-coupled inhibitory neurons predominantly in the striatonigral, mesolimbic, and tuberoinfundibular systems. They inhibit adenylyl cyclase and calcium (Ca2+) channels and activate potassium channels leading to their physiological functions. The exact mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, however, it is believed to be related to its ability to selectively stimulate dopamine D2 receptors within the caudate-putamen system in the brain. This system affects body movement. Negligible affinity is seen for ropinirole at α2 adrenoreceptors in the periphery and 5HT-1 receptor. Ropinirole has no affinity at the D1-like receptors, benzodiazepine or GABA receptors

PW126560

Pw126560 View Pathway
drug action

Ropivacaine

Homo sapiens
Ropivacaine an aminoamide analgesic is a racemic mixture of "S" and "R" enantiomers used for local anesthesia or for short term management of pain. Ropivacaine acts to block generation and propagation of action potentials by increasing the threshold for electrical excitation. This is done by blocking the sodium channel which causes a inhibits depolarization and decreases action potentials. Ropivacaine is metabolized in the liver by cytochrome P4501A through aromatic hydroxylation. The resulting metabolite 3-hydroxy ropivacaine is excreted by diruesis. Precaution should be taken with high systemic doses of ropivacaine which can effect the central nervous system and cardiovascular system.

PW000410

Pw000410 View Pathway
drug action

Ropivacaine Action Pathway

Homo sapiens
Ropivacaine exerts its local anaesthetic effect by blocking voltage-gated sodium channels in peripheral neurons. Ropivacaine diffuses across the neuronal plasma membrane in its uncharged base form. Once inside the cytoplasm, it is protonated and this protonated form enters and blocks the pore of the voltage-gated sodium channel from the cytoplasmic side. For this to happen, the sodium channel must first become active so that so that gating mechanism is in the open state. Therefore ropivacaine preferentially inhibits neurons that are actively firing.